Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 5/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366319 | 0.87 | KDM4E (0.48) | NR3C1LMNAHTTPDE9APDE1A | |
| SCHEMBL6365929 | 0.83 | PDE5A (0.53) | NR3C1PDE9APDE5APDE1APDE1B | |
| SCHEMBL6371104 | 0.82 | MEN1 (0.40) | NR3C1LMNAPDE9APDE5APDE1A | |
| SCHEMBL6367367 | 0.80 | CXCR2 (0.32) | PDE5APDE1APDE1BPDE1CPIM1 | |
| SCHEMBL6366723 | 0.79 | AR (0.39) | PDE9APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL6366854 | 0.79 | CCR2 (0.39) | PDE9APDE5APDE1APDE1BPDE1C | |
| SCHEMBL6367286 | 0.78 | LMNA (0.40) | NR3C1LMNAMAPTDAO | |
| SCHEMBL6366999 | 0.78 | PDE9A (0.48) | NR3C1LMNAHTTNPSR1CA5A | |
| SCHEMBL6366342 | 0.76 | AR (0.42) | PDE9APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL6365889 | 0.76 | PNP (0.44) | NR3C1PDE9APDE5APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | NR3C1 1526/4885LMNA 1866/4885HTT 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.